| Code | CSB-RA004847MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to CM369, targeting CCR8 (C-C motif chemokine receptor 8), a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper cell subsets. CCR8 mediates chemotaxis in response to its ligands CCL1 and CCL18, playing a crucial role in immune regulation and T cell trafficking to tissues. This receptor has emerged as a significant marker of tumor-infiltrating Tregs across multiple cancer types, where it contributes to the immunosuppressive tumor microenvironment by facilitating Treg accumulation and function.
CM369 is a reference antibody that has been utilized in preclinical research to investigate CCR8's role in cancer immunology and autoimmune disorders. This biosimilar provides researchers with a valuable tool for studying CCR8-mediated immune regulation, exploring therapeutic strategies targeting tumor-associated Tregs, and investigating the receptor's involvement in inflammatory diseases. The antibody supports investigations into immunotherapy approaches and mechanisms of immune evasion in oncology research.
There are currently no reviews for this product.